<DOC>
	<DOCNO>NCT02231450</DOCNO>
	<brief_summary>The purpose study assess impact mild moderate hepatic impairment pharmacokinetics Lu AE58054 follow single oral dose Lu AE58054</brief_summary>
	<brief_title>Pharmacokinetics Properties Single Oral Dosing Lu AE58054 Subjects With Hepatic Impairment ( Mild Moderate ) Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Men woman age 40 65 year ( inclusive ) body mass index 19 32 kg/m2 ( inclusive ) . Group 1 : Patients mild hepatic impairment ( ChildPugh 's Criteria A , score 56 ) Group 2 : Patients moderate hepatic impairment ( ChildPugh 's Criteria B , score 79 ) Group 3 : Healthy subject normal hepatic function Other predefined inclusion exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>AE58054</keyword>
	<keyword>Hepatic impairment</keyword>
</DOC>